View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 7, 2022

Pfizer plans $120m investment for Covid-19 oral drug manufacturing in US

The latest expansion will create more than 250 new high-skilled manufacturing jobs at the company’s Kalamazoo facility.

Pfizer has announced plans to invest $120m in its manufacturing facility in Kalamazoo, Michigan, US, to produce its Covid-19 oral drug, Paxlovid (nirmatrelvir [PF-07321332] tablets and ritonavir tablets).

The new investment will help in expanding the active pharmaceutical ingredient (API) and registered starting materials (RSMs) production.

They are used to produce the novel main protease (Mpro) inhibitor, nirmatrelvir.

This expansion will create more than 250 new manufacturing jobs at the Kalamazoo facility.

Pfizer stated that the expansion of API and RSMs production for nirmatrelvir will allow it to increase the Paxlovid supply capacity to meet the worldwide demand.

The company has shipped 12 million Paxlovid courses across 37 countries, including five million shipped to the US, till date.

Pfizer chief global supply officer Mike McDermott said: “The Kalamazoo facility uses some of our most innovative manufacturing technology and has been essential in Pfizer’s fight against Covid-19, producing nearly one billion doses of Covid-19 vaccine at the site to date.

“Through this expansion, we will continue to invest in the next generation of manufacturing and supply chain resilience.”

In Kalamazoo, the company is also planning to expand its Modular Aseptic Processing (MAP) sterile injectable pharmaceutical production site.

The latest expansion follows a $450m investment in phase one to build a 400,000ft2 production plant.

In January this year, Pfizer received Health Canada authorisation for its cocktail of two antiviral drugs, nirmatrelvir and ritonavir, to treat adult patients with mild-to-moderate Covid-19.

Paxlovid, the combination therapy, is intended for the treatment of individuals who are at increased risk of disease progression, including hospital admission or death.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology